Hartland,

This is just a short term (3 day) pharmacokinetic/safety trial in 8 healthy patients and 8 patients with severe kidney disease to show that a single dose of RVX-208 isn't metabolized any differently when kidneys are compromised. They are planning to collect blood data to analyze with the Coloroda SomaScan technology (as they did for ASSERT/ASSURE), but it will only be from this single dose over 3 days.

BearDownAZ